Recent Progress of Small-molecule-based Theranostic Agents in Alzheimer's Disease

Overview

Journal RSC Med Chem

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2023 Nov 17

PMID 37974955

Authors

Furong Gao

Jiefang Chen

Yuancun Zhou

Letong Cheng

Ming Hu

Xiaohui Wang

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is the most common form of neurodegenerative dementia. As a multifactorial disease, AD involves several etiopathogenic mechanisms, in which multiple pathological factors are interconnected with each other. This complicated and unclear pathogenesis makes AD lack effective diagnosis and treatment. Theranostics, exerting the synergistic effect of diagnostic and therapeutic functions, would provide a promising strategy for exploring AD pathogenesis and developing drugs for combating AD. With the efforts in small drug-like molecules for both diagnosis and treatment of AD, small-molecule-based theranostic agents have attracted significant attention owing to their facile synthesis, high biocompatibility and reproducibility, and easy clearance from the body through the excretion systems. In this review, the small-molecule-based theranostic agents reported in the literature for anti-AD are classified into four groups according to their diagnostic modalities. Their design rationales, chemical structures, and working mechanisms for theranostics are summarized. Finally, the opportunities for small-molecule-based theranostic agents in AD are also proposed.

References

Mosconi L, Mistur R, Switalski R, Tsui W, Glodzik L, Li Y . FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2009; 36(5):811-22. PMC: 2774795. DOI: 10.1007/s00259-008-1039-z. View

Wang Y, Mandelkow E . Tau in physiology and pathology. Nat Rev Neurosci. 2015; 17(1):5-21. DOI: 10.1038/nrn.2015.1. View

Feng Z, Tang T, Wu T, Yu X, Zhang Y, Wang M . Perfecting and extending the near-infrared imaging window. Light Sci Appl. 2021; 10(1):197. PMC: 8463572. DOI: 10.1038/s41377-021-00628-0. View

McNerney M, Doiron K, Ng T, Chang T, Silver P . Theranostic cells: emerging clinical applications of synthetic biology. Nat Rev Genet. 2021; 22(11):730-746. PMC: 8261392. DOI: 10.1038/s41576-021-00383-3. View

Karran E, Mercken M, De Strooper B . The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011; 10(9):698-712. DOI: 10.1038/nrd3505. View

Ramesh M, Govindaraju T . Multipronged diagnostic and therapeutic strategies for Alzheimer's disease. Chem Sci. 2022; 13(46):13657-13689. PMC: 9710308. DOI: 10.1039/d2sc03932j. View

Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T . Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression. Cell Res. 2019; 29(10):787-803. PMC: 6796854. DOI: 10.1038/s41422-019-0216-x. View

Kepp K . Bioinorganic chemistry of Alzheimer's disease. Chem Rev. 2012; 112(10):5193-239. DOI: 10.1021/cr300009x. View

Li C, Yang L, Han Y, Wang X . A simple approach to quantitative determination of soluble amyloid-β peptides using a ratiometric fluorescence probe. Biosens Bioelectron. 2019; 142:111518. DOI: 10.1016/j.bios.2019.111518. View

10.

Muthuraj B, Layek S, Balaji S, Trivedi V, Iyer P . Multiple function fluorescein probe performs metal chelation, disaggregation, and modulation of aggregated Aβ and Aβ-Cu complex. ACS Chem Neurosci. 2015; 6(11):1880-91. DOI: 10.1021/acschemneuro.5b00205. View

11.

Blennow K . Biomarkers in Alzheimer's disease drug development. Nat Med. 2010; 16(11):1218-22. DOI: 10.1038/nm.2221. View

12.

Zhang X, Tian Y, Li Z, Tian X, Sun H, Liu H . Design and synthesis of curcumin analogues for in vivo fluorescence imaging and inhibiting copper-induced cross-linking of amyloid beta species in Alzheimer's disease. J Am Chem Soc. 2013; 135(44):16397-409. PMC: 3927838. DOI: 10.1021/ja405239v. View

13.

Li Q, Min J, Ahn Y, Namm J, Kim E, Lui R . Styryl-based compounds as potential in vivo imaging agents for beta-amyloid plaques. Chembiochem. 2007; 8(14):1679-87. DOI: 10.1002/cbic.200700154. View

14.

Sarabia-Vallejo A, Lopez-Alvarado P, Menendez J . Small-molecule theranostics in Alzheimer's disease. Eur J Med Chem. 2023; 255:115382. DOI: 10.1016/j.ejmech.2023.115382. View

15.

Barthelemy N, Horie K, Sato C, Bateman R . Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. J Exp Med. 2020; 217(11). PMC: 7596823. DOI: 10.1084/jem.20200861. View

16.

Wang X, Chan H, Desbois N, Gros C, Bolze F, Li Y . Multimodal Theranostic Cyanine-Conjugated Gadolinium(III) Complex for Imaging of Amyloid-β in an Alzheimer's Disease Mouse Model. ACS Appl Mater Interfaces. 2021; 13(16):18525-18532. DOI: 10.1021/acsami.1c01585. View

17.

Yang Y, Li S, Zhang Q, Kuang Y, Qin A, Gao M . An AIE-active theranostic probe for light-up detection of Aβ aggregates and protection of neuronal cells. J Mater Chem B. 2020; 7(15):2434-2441. DOI: 10.1039/c9tb00121b. View

18.

Syed Y . Sodium Oligomannate: First Approval. Drugs. 2020; 80(4):441-444. DOI: 10.1007/s40265-020-01268-1. View

19.

Kulenkampff K, Wolf Perez A, Sormanni P, Habchi J, Vendruscolo M . Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. Nat Rev Chem. 2023; 5(4):277-294. DOI: 10.1038/s41570-021-00254-9. View

20.

Wang X, Wang C, Chan H, Ashok I, Krishnamoorthi S, Li M . Amyloid-β oligomer targeted theranostic probes for in vivo NIR imaging and inhibition of self-aggregation and amyloid-β induced ROS generation. Talanta. 2020; 224:121830. DOI: 10.1016/j.talanta.2020.121830. View